Study summary · research use only
Human chorionic gonadotropin (hCG) beta-core fragment is produced by degradation of hCG or free hCG beta in gestational trophoblastic tumors: a possible marker for early detection of persistent postmolar gestational trophoblastic disease
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This human study examined tissue and serum samples from patients with gestational trophoblastic disease (hydatidiform mole and choriocarcinoma) to determine whether human chorionic gonadotropin (hCG) beta-core fragment (hCG beta cf) is produced directly by these tumors. The authors reported hCG beta cf immunoreactivity in mole and choriocarcinoma tissue extracts and culture media, localized to syncytiotrophoblasts, at levels exceeding intact hCG in tissue but present at a much lower ratio in serum. Serial serum measurements after mole evacuation showed hCG beta cf declined faster than hCG and became undetectable in patients with spontaneous resolution, while it persisted or reappeared before hCG rose in patients who later developed persistent disease. The authors suggested serum hCG beta cf monitoring may help predict subsequent persistent trophoblastic disease.
Abstract
The present study was undertaken to investigate whether human chorionic gonadotropin (hCG) beta-core fragment (hCG beta cf) was directly produced by gestational trophoblastic tumors. Immunoreactivity of hCG beta cf was demonstrated in the extracts as well as in the culture media of hydatidiform mole tissues. It was also present in the extracts of choriocarcinoma tissues, and its molar concentration exceeded that of intact hCG. The presence of hCG beta cf was then confirmed by gel chromatography and Western blot analysis. Immunohistochemistry showed localization of hCG beta cf immunoreactivity to the syncytiotrophoblasts and scattered cells in the stroma of mole tissue, and to syncytiotrophoblastic cells in choriocarcinoma. Immunoreactivity of hCG beta cf was also detected in the sera of the patients with gestational trophoblastic disease, although the hCG beta cf/hCG ratio was less than one hundredth of that in the tissue extracts. Serial measurement of serum hCG beta cf levels after mole evacuation showed that they declined much more rapidly than those of hCG and became undetectable in the patients with subsequent spontaneous resolution, while hCG beta cf remained or became detectable before the rise of hCG was observed in the patients with subsequent persistent trophoblastic disease. Taken together, these results suggest that hCG beta cf is directly produced by gestational trophoblastic tumors, and monitoring of hCG beta cf in the serum after mole evacuation may be useful for early prediction of subsequent development of postmolar persistent trophoblastic disease.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.